Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.060x

Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥44.34 Million ≈ $6.49 Million USD) by net assets (CN¥735.65 Million ≈ $107.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Hainan Huluwa Pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Hainan Huluwa Pharmaceutical Group Co Lt (605199) financial obligations for a breakdown of total debt and financial obligations.

Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hainan Huluwa Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Companhia Brasileira de Distribuição MX:CBDN	-0.073x
Taiwan Steel Union Co Ltd TW:6581	0.035x
HEIDELB.DRUCK.UNS.ADR 1/2 F:HDDF	N/A
MK Electron Co. Ltd KQ:033160	-0.039x
Commercial Bancgroup, Inc. Common Stock NASDAQ:CBK	0.032x
Samhi Hotels Limited NSE:SAMHI	0.014x
Natures Sunshine Products Inc NASDAQ:NATR	0.111x
Panoro Energy ASA F:1PZ	0.140x

Annual Cash Flow Conversion Efficiency for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Hainan Huluwa Pharmaceutical Group Co Lt.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥743.28 Million ≈ $108.77 Million	CN¥-149.12 Million ≈ $-21.82 Million	-0.201x	-923.26%
2023-12-31	CN¥1.16 Billion ≈ $169.65 Million	CN¥28.25 Million ≈ $4.13 Million	0.024x	-89.64%
2022-12-31	CN¥1.02 Billion ≈ $148.57 Million	CN¥238.71 Million ≈ $34.93 Million	0.235x	+113.48%
2021-12-31	CN¥930.52 Million ≈ $136.16 Million	CN¥102.48 Million ≈ $15.00 Million	0.110x	+2958.79%
2020-12-31	CN¥916.48 Million ≈ $134.11 Million	CN¥3.30 Million ≈ $482.88K	0.004x	-98.40%
2019-12-31	CN¥643.94 Million ≈ $94.23 Million	CN¥144.51 Million ≈ $21.15 Million	0.224x	+326.73%
2018-12-31	CN¥604.61 Million ≈ $88.47 Million	CN¥31.80 Million ≈ $4.65 Million	0.053x	-79.46%
2017-12-31	CN¥351.38 Million ≈ $51.42 Million	CN¥89.96 Million ≈ $13.16 Million	0.256x	-49.28%
2016-12-31	CN¥128.69 Million ≈ $18.83 Million	CN¥64.96 Million ≈ $9.51 Million	0.505x	--

About Hainan Huluwa Pharmaceutical Group Co Ltd

SHG:605199 China Drug Manufacturers - Specialty & Generic

Market Cap

$383.49 Million

CN¥2.62 Billion CNY

Market Cap Rank

#13904 Global

#4368 in China

Share Price

CN¥6.55

Change (1 day)

-3.53%

52-Week Range

CN¥6.12 - CN¥10.65

All Time High

CN¥48.21